Myelofibrosis is a type of leukemia, a group of cancers that affect your blood and bone marrow (where blood cells are made). The disease can happen because of a change in your genes (called ...

When the gene becomes mutated your bone marrow may not function correctly. This means scar tissue can build up in your bone marrow. About 10 in 100 people with primary myelofibrosis (around 10%) will ...

High levels may also be a sign of myelofibrosis. Bone Marrow Tests. Your doctor will likely perform two bone marrow tests. They can do them at the same time in their office or in the hospital.

Join Drs Tania Jain and Rachel Salit as they explore evolving definitions of remission, relapse monitoring, and patient-centered transplant decisions in myelofibrosis care.

Myelofibrosis is a rare bone marrow cancer. Complications may include enlarged spleen and noncancerous tumors, among others. Learn the complications and how to reduce your risk.

Post-MPN AML is defined as the presence of 20% or more myeloblasts in the peripheral blood or bone marrow of a patient with ...

--Galecto, Inc., a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive results from a planned intermediate ...

Primary myelofibrosis (MF) is a rare cancer that causes a buildup of scar tissue, known as fibrosis, in the bone marrow. This prevents your bone marrow from producing a healthy amount of blood ...

Primary myelofibrosis (PMF) is a rare bone marrow disorder that affects the production of blood cells. It causes scarring, or fibrosis, in the bone marrow, which reduces the body’s ability to ...

Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise. Annual incidence rates for 2000 to 2012 ranged from 0.1 to 1.0 per 100,000. Prevalence ...

Sequencing Therapy. In a study in Cancer among 524 patients who received ruxolitinib for myelofibrosis, about 40.8% discontinued treatment at 3 years. The reasons for discontinuation included lack ...

Pelabresib (CPI-0610) plus Jakafi (ruxolitinib) continued to reduce splenomegaly, anemia, symptoms and bone marrow fibrosis in patients with JAK inhibitor-naive myelofibrosis, recent study findings ...